Exploration of neuroscience,
Journal Year:
2025,
Volume and Issue:
4
Published: Feb. 25, 2025
Alzheimer’s
disease
(AD)
is
a
neurodegenerative
disorder
that
affects
millions
of
people
worldwide.
It
presents
significant
challenge
in
terms
accurate
diagnosis,
progression
monitoring,
and
the
development
effective
treatments.
This
article
addresses
role
neuroimaging
as
an
advancing
tool
for
monitoring
progression,
treatment
AD.
A
comprehensive
review
existing
literature
on
use
AD
was
conducted
using
various
databases.
The
different
imaging
techniques,
such
magnetic
resonance
(MRI),
single
photon
emission
computed
tomography
(SPECT),
positron
(PET),
were
examined
their
ability
to
detect
amyloid
beta
(Aβ)
plaques
neurofibrillary
tangles
(NFTs),
hallmark
pathological
features
Neuroimaging
enables
visualization
Alzheimer-related
biomarkers,
Aβ
plaques,
tau
protein
tangles,
neuro-inflammation,
synaptic
dysfunction,
providing
valuable
insights
into
pathophysiology
progression.
These
techniques
assist
early
detection
AD,
distinguishing
it
from
other
conditions
evaluating
effectiveness
has
potential
significantly
transform
way
managed
clinically.
By
molecular
changes
occur
brain
during
course
disease,
can
facilitate
monitor
inform
decisions.
Furthermore,
holds
great
accelerating
drug
by
allowing
researchers
assess
efficacy
novel
therapies
real
time.
Overall,
integration
clinical
management
revolutionize
we
approach
treatment,
research
Journal of Alzheimer s Disease,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 2, 2025
Background
Immune
dysregulation
has
been
implicated
in
Alzheimer's
disease;
however,
precise
mechanisms
and
timing
have
not
established.
Objective
To
investigate
the
concurrent
longitudinal
associations
of
serum
C-reactive
protein
(CRP)
dietary
inflammatory
index
(DII)
with
cognitive
decline
as
observed
disease.
Methods
The
study
was
based
on
7613
individuals
who
participated
Tromsø6
(2007–2008)
Tromsø7
(2015–2016).
We
analyzed
relationship
between
CRP
levels,
DII,
function
cross-sectionally
using
linear
regression.
used
mediation
analysis
to
examine
if
mediates
effects
DII
function.
Further,
we
related
baseline
change
after
7
years
follow
up.
mixed
models
relate
changes
levels
measured
at
two
time
points
apart.
Results
Both
level
were
inversely
associated
(psychomotor
speed,
executive
function).
There
no
prospective
Increase
decrease
function,
verbal
memory)
measurements
model
did
show
convincing
evidence
a
mediating
effect
association
diet
Conclusions
After
comprehensive
CRP,
conclude
that
is
likely
reflect
environment
occurring
parallel
decline.
Frontiers in Chemistry,
Journal Year:
2025,
Volume and Issue:
13
Published: Feb. 4, 2025
Therapeutic
strategies
for
Alzheimer’s
disease
(AD)
often
involve
inhibiting
acetylcholinesterase
(AChE),
underscoring
the
need
novel
inhibitors
with
high
selectivity
and
minimal
side
effects.
A
detailed
analysis
of
protein-ligand
pharmacophore
dynamics
can
facilitate
this.
In
this
study,
we
developed
employed
dyphAI
,
an
innovative
approach
integrating
machine
learning
models,
ligand-based
complex-based
models
into
a
model
ensemble.
This
ensemble
captures
key
interactions,
including
π-cation
interactions
Trp-86
several
π-π
residues
Tyr-341,
Tyr-337,
Tyr-124,
Tyr-72.
The
protocol
identified
18
molecules
from
ZINC
database
binding
energy
values
ranging
−62
to
−115
kJ/mol,
suggesting
their
strong
potential
as
AChE
inhibitors.
To
further
validate
predictions,
nine
were
acquired
tested
inhibitory
activity
against
human
AChE.
Experimental
results
revealed
that
molecules,
4
(P-1894047),
its
complex
multi-ring
structure
numerous
hydrogen
bond
acceptors,
7
(P-2652815),
characterized
by
flexible,
polar
framework
ten
donors
exhibited
IC₅₀
lower
than
or
equal
control
(galantamine),
indicating
potent
activity.
Similarly,
5
(P-1205609),
6
(P-1206762),
8
(P-2026435),
9
(P-533735)
also
demonstrated
inhibition.
contrast,
molecule
3
(P-617769798)
showed
higher
IC
50
value,
1
(P-14421887)
2
(P-25746649)
yielded
inconsistent
results,
likely
due
solubility
issues
in
experimental
setup.
These
findings
underscore
value
computational
predictions
validation,
enhancing
reliability
virtual
screening
discovery
enzyme
Journal of Alzheimer s Disease,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 16, 2025
Background
Alzheimer's
disease
(AD)
has
become
common
as
the
number
of
aged
people
increases
making
it
a
socioeconomic
problem
lately.
To
date,
no
success
is
recorded
for
disease-modifying
therapies
AD
but
only
drugs
symptomatic
relief
exist.
Research
been
centered
on
role
amyloid-β
pathogenesis
AD,
which
led
to
development
that
target
Aβ
(β-
and
γ-secretase
inhibitors)
reduce
amount
formed.
However,
existing
β
inhibitors
were
associated
with
harmful
side
effects,
low
efficacy,
inability
cross
blood-brain
barrier.
Objective
This
study
therefore
used
in
silico
approach
predict
inhibitory
properties
alkaloids
potential
drug
targets
against
AD.
Methods
Thus,
this
current
study,
54
from
PhytoHub
server
(phytohub.eu),
two
approved
docked
β-secretases.
Additionally,
galantamine
5
utmost
binding
β-secretase
subjected
pharmacokinetics
evaluation
γ-secretase.
Results
From
result,
compounds
displayed
both
docking
periods,
demissidine,
solasodine,
tomatidine,
solanidine
having
better
BE
than
control
drugs.
Based
evaluation,
4
possessed
good
pharmacokinetic
biological
activities
galantamine.
Conclusions
suggests
are
promising
dual
β-
proteins
silico.
there
an
urgent
need
carry
out
vitro
vivo
experiments
these
new
leads
validate
findings
study.
Nature Communications,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Feb. 19, 2025
Repurposed
drugs
provide
a
rich
source
of
potential
therapies
for
Alzheimer's
disease
(AD)
and
other
neurodegenerative
disorders
(NDD).
have
information
from
non-clinical
studies,
phase
1
dosing,
safety
tolerability
data
collected
with
the
original
indication.
Computational
approaches,
"omic"
drug
databases,
electronic
medical
records
help
identify
candidate
therapies.
Generic
repurposed
agents
lack
intellectual
property
protection
are
rarely
advanced
to
late-stage
trials
AD/NDD.
In
this
review
we
define
repurposing,
describe
advantages
challenges
offer
strategies
overcoming
obstacles,
key
contributions
repurposing
development
ecosystem.
review,
authors
discuss
obstacles
development.
Exploration of neuroscience,
Journal Year:
2025,
Volume and Issue:
4
Published: Feb. 25, 2025
Alzheimer’s
disease
(AD)
is
a
neurodegenerative
disorder
that
affects
millions
of
people
worldwide.
It
presents
significant
challenge
in
terms
accurate
diagnosis,
progression
monitoring,
and
the
development
effective
treatments.
This
article
addresses
role
neuroimaging
as
an
advancing
tool
for
monitoring
progression,
treatment
AD.
A
comprehensive
review
existing
literature
on
use
AD
was
conducted
using
various
databases.
The
different
imaging
techniques,
such
magnetic
resonance
(MRI),
single
photon
emission
computed
tomography
(SPECT),
positron
(PET),
were
examined
their
ability
to
detect
amyloid
beta
(Aβ)
plaques
neurofibrillary
tangles
(NFTs),
hallmark
pathological
features
Neuroimaging
enables
visualization
Alzheimer-related
biomarkers,
Aβ
plaques,
tau
protein
tangles,
neuro-inflammation,
synaptic
dysfunction,
providing
valuable
insights
into
pathophysiology
progression.
These
techniques
assist
early
detection
AD,
distinguishing
it
from
other
conditions
evaluating
effectiveness
has
potential
significantly
transform
way
managed
clinically.
By
molecular
changes
occur
brain
during
course
disease,
can
facilitate
monitor
inform
decisions.
Furthermore,
holds
great
accelerating
drug
by
allowing
researchers
assess
efficacy
novel
therapies
real
time.
Overall,
integration
clinical
management
revolutionize
we
approach
treatment,
research
